Today: 20 May 2026
Reckitt Benckiser shares slip after RBC downgrade as buybacks and dividend vote loom
15 January 2026
1 min read

Reckitt Benckiser shares slip after RBC downgrade as buybacks and dividend vote loom

London, Jan 15, 2026, 09:37 GMT — Regular session

  • Reckitt shares dipped in early London trading following RBC’s decision to downgrade its rating and slash the target price
  • RBC highlighted doubts over 2026 margins and the lingering impact of the Mead Johnson litigation
  • Investors are keeping an eye on a January 27 shareholder vote linked to a £1.6 billion special dividend

Shares of Reckitt Benckiser Group plc slipped Thursday, dropping 0.2% to 6,170 pence by mid-morning in London, following a downgrade from RBC Capital Markets. The broker flagged valuation concerns after the company sold its Essential Home unit.

The call comes at a tricky time for investors. Reckitt is seeking shareholder approval for a sizable one-off cash return and a share consolidation, even as the market awaits firmer guidance on profitability in 2026.

It’s crucial now since those two paths are diverging. A special dividend would deliver cash fast, yet “stranded costs” — overheads lingering after a sale — could squeeze margins until management adjusts the cost structure.

RBC analyst James Edwardes Jones flagged that the broker’s updated figures are “not the finished article,” pointing to missing guidance on margin expansion in 2026 post-Essential Home sale. He factored in a 60 basis point drop in EBIT margin — with one basis point equal to 0.01 percentage point — and included a £2 billion global settlement in his model for U.S. necrotising enterocolitis (NEC) claims tied to Mead Johnson. The first bellwether case is expected in February. Investing.com

Reckitt disclosed another modest buyback, acquiring 48,660 shares on Jan. 14 at a volume-weighted average price of 6,162.77 pence. The company plans to hold these shares in treasury. The filing updates total voting rights to 671,991,359, the number investors rely on for UK disclosure rules.

The company plans a special dividend of 235 pence per share, totaling around £1.6 billion. It also proposes a 24-for-25 share consolidation to keep the share price roughly stable post-dividend. Shareholders will vote on the proposal at a general meeting on Jan. 27, with the dividend slated for payment on Feb. 20 if approved.

A consolidation essentially resets the share count: investors end up with fewer shares, but each one should carry a higher value, assuming everything else stays the same. Traders, however, keep an eye on potential snags—like shifts in index weightings, fund mandates, and how seamlessly the process unfolds.

The key “but” remains: none of the major uncertainties have been resolved. If stranded costs hit margins harder than anticipated, or if the NEC litigation takes a negative turn, the market’s perception of this as a defensive, cash-return play could shift sharply.

Investors will be watching closely for broker follow-up after RBC’s move while also tracking price action near the 6,200 pence mark, now aligned with RBC’s target.

Coming up next: the Jan. 27 shareholder meeting to vote on the special dividend and consolidation. Then there’s the February NEC bellwether case, which RBC says might shape settlement discussions. Both events lead up to the Feb. 20 payout date.

Stock Market Today

  • Oil Prices Fall After Trump Comments on Ending Iran War
    May 20, 2026, 7:14 AM EDT. Oil prices declined on Tuesday following President Trump's statement reaffirming his intent to end the conflict with Iran "very quickly." The Strait of Hormuz, a critical chokepoint for global oil shipments, experienced one of its busiest days since its recent closure, underscoring the region's importance to energy markets and the potential impact of geopolitical developments on supply dynamics.

Latest articles

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

20 May 2026
InMed Pharmaceuticals shares fell 14.4% to $1.37 in early pre-market trading Wednesday, after surging 135% Tuesday on news of an all-stock merger with Mentari Therapeutics and a planned $290 million private placement. Pre-merger InMed shareholders are expected to own about 1.51% of the combined company, which will operate as Mentari Therapeutics and focus on migraine drug development.
Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

20 May 2026
Micware shares jumped 97.7% to $9.33 in premarket U.S. trading Wednesday, rebounding above last week’s $8 IPO price after closing Tuesday at $4.72. A new SEC filing showed Toyota owns 11.6% of Micware’s ordinary shares. The Japanese automotive software firm raised $22.8 million in its Nasdaq debut last week.
Dow edges up while Nasdaq falls as bond worries drag on

Futures Edge Higher Ahead of Nvidia Earnings as Wall Street Watches Key Report

20 May 2026
Nasdaq 100 futures rose 0.73% and S&P 500 futures gained 0.35% ahead of Wednesday’s open, with Nvidia set to report earnings after the close. Options markets priced in a 6.5% swing for Nvidia, equal to about $355 billion in market value. In premarket trading, Nvidia shares rose 1.84%, while Micron, Intel, and AMD also advanced. Fed minutes are due at 2:00 p.m. EDT.
BP stock slides in London as $5 billion write-down warning puts buyback in focus
Previous Story

BP stock slides in London as $5 billion write-down warning puts buyback in focus

Broadcom stock falls again as China targets VMware; RBC says OpenAI upside ‘less clear’
Next Story

Broadcom stock falls again as China targets VMware; RBC says OpenAI upside ‘less clear’

Go toTop